Northrop Grumman Corporation

Executive Summary

Rated BUY, Medium conviction. Quant price target is $1007.69, or 83.5% above the current $549.04, with a quality score of 54/100 and risk score of 36/100 (Low). The stock has fallen to 29.1% below its 52-week high and trades 10.4% below its 200-day average even as the company enters a year where revenue, margin, and especially cash flow should improve.

The core question is not whether NOC looks cheap on trailing numbers. It does. The real question is whether investors trust the step-up in B-21 and Sentinel to convert into higher earnings quality and cash generation. Current pricing says no. The data says that skepticism has become too severe.

Investment Thesis

NOC is in the middle of a portfolio shift toward programs the Pentagon is unlikely to cut, strategic deterrence, long-range strike, and munitions capacity. The evidence is specific. B-21 production rate is increasing by 25%, Sentinel is expected to grow low double-digit in FY26, and first-quarter awards were $9.8B, ending with $96B of backlog.

This matters because the stock is not priced for a company with accelerating capacity and backlog visibility. It is priced at 17.11x earnings and 1.84x sales versus peer averages of 30.7x and 3.8x. That discount would make sense if margins were deteriorating and execution were slipping. Instead, FY2025 operating margin improved to 10.9% from 10.6%, Q1 2026 segment margin reached 10.8%, and EBITDA margin improved 450 bps y/y to 15.8%.

The market's objection is cash flow. Fair enough. FY2025 free cash flow was negative $1.8B. But management is guiding to $3.1B-$3.5B in FY26 even with $1.85B of CapEx, largely tied to B-21 capacity expansion. If that conversion shows up, the discount should narrow.

Financial Strength

The balance sheet is acceptable, not pristine. Total debt stands at $17.1B, Debt/Equity is 1.00, and Debt/EBITDA is 2.37x. The current ratio is 1.14, which leaves little room for another cash stumble. That is why the cash flow guide matters more than the income statement this year.

Still, NOC is not facing a demand problem. Revenue in FY2025 grew 2.3% to $42.0B, and Q1 2026 sales rose 4% y/y to $9.9B. The issue is timing of working capital, program ramp costs, and elevated investment. Those are manageable if the largest programs move as expected. They become a real problem only if schedule friction persists while CapEx stays high.

Competitive Position

NOC's moat is tied to mission-critical, technically hard, and politically protected programs. B-21, Sentinel, restricted programs, TACAMO, and solid rocket motors sit inside U.S. strategic priorities. These are not commodity contracts.

Capacity also matters. Management said it added 20+ new facilities and more than 2M square feet in the last two years. It also said tactical solid rocket motor capacity has already doubled, with further expansion completing by 2027. In a market where munitions deliveries remain constrained, owning installed capacity is a competitive advantage.

AI is not a threat to this moat. It should strengthen it. The company benefits as autonomy, sensor fusion, battle management, and digital engineering become more important inside advanced platforms. The risk is not AI disruption. The risk is program oversight and milestone timing, especially on Sentinel.

Management & Guidance

Management credibility is decent. NOC beat EPS in 7 of the last 8 quarters. The beats were not token either, with +19.1% on 2025-10-21 and +15.3% on 2024-10-24. The one miss, -2.9% on 2025-04-22, does not suggest a broken execution story.

On the Q1 2026 call, CFO John Green said: "We are reaffirming our outlook for sales, earnings, and cash. We ended the first quarter with positive momentum and continue to expect full year results within the existing guidance ranges." That caution cuts both ways. It is a reminder that management still sees enough uncertainty not to raise numbers after a good quarter.

There was also a direct volume signal for Q2. Green said: "For the second quarter, we expect high single-digit sequential sales growth, and for the full year, we continue to expect broad-based sales growth across the portfolio." CEO Kathy Warden added: "As previously announced, we finalized an agreement with the Air Force to increase the annual production rate of the B-21 by 25%." On Sentinel timing, Warden said: "We expect to reach the Milestone B decision later this year, first flight in 2027, and initial operating capability in the early 2030s."

Those comments support the growth case. They do not eliminate execution risk.

Bull Case

The bull case rests on three linked changes. First, a better program mix is lifting earnings quality. The absence of the prior-year B-21 loss provision helped Q1 margin, and management explicitly said the B-21 deal improves long-term economics and ROIC.

Second, the cash profile should inflect sharply. Going from -$1.8B in FY2025 free cash flow to $3.1B-$3.5B in FY26 is not a small cleanup. It is the difference between a balance-sheet concern and a self-funded growth story.

Third, the stock is washed out enough to matter. NOC is down 18.51% over three months, even after a 10.69% one-week rebound. At $549.04, much of the sentiment damage is already in the price.

Bear Case

The bear case is also concrete. The biggest issue is that the cash rebound may slip. Elevated $1.85B CapEx, working capital needs, and large-program timing can keep free cash flow volatile longer than investors expect.

Space is another problem area. Q1 included a $71M unfavorable adjustment on GEM 63XL, and management flagged year-over-year pressure from an NGI comparison. That weakens the argument that all segments are moving together.

Finally, valuation support is less bulletproof than it looks. The quant target uses peer frameworks where the 10-peer group shows wide dispersion of 3.6x in P/E. That means a simple move toward peer averages is not a dependable base case.

Valuation & Price Target

The quant engine sets a $1007.69 price target on an earnings_growth_blend basis, with method outputs of P/E Multiple $1017.1, P/S Multiple $1380.36, Quality-adjusted $611.94, and DCF $1051.15. That spread says the same thing the market is saying: NOC looks very cheap if the growth and cash conversion story holds, and only modestly undervalued if quality concerns persist.

The right way to read that mix is not to grab the highest number. It is to note that even the conservative quality-adjusted value is $611.94, still above the current $549.04. With a trailing 17.11x P/E against visible FY26 growth, the stock does not need a heroic re-rating to work.

Risk Assessment

The single biggest risk is execution on the cash and schedule side. Sentinel Milestone B later this year is critical. If milestone timing slips, or if B-21 ramp costs outrun improved economics, the expected move to $3.1B-$3.5B of free cash flow could disappoint.

Secondary risks are measurable. Leverage at 2.37x Debt/EBITDA is manageable but not trivial. Liquidity at a 1.14 current ratio is adequate but thin. Space segment pressure is real, with the $71M GEM 63XL adjustment already showing up in results.

The Bottom Line

NOC is not a clean story, but it is a mispriced one. The market is fixated on last year's negative $1.8B free cash flow and near-term program complexity, while ignoring that the company has a $96B backlog, a 25% higher B-21 production rate, low double-digit Sentinel growth, and FY26 guidance that implies a real cash recovery. At $549.04, the stock is being valued like a company with stagnant earnings power. The business is headed in the opposite direction.